Alimera Sciences Closes $37.5 Million Private Placement
ATLANTA, Feb. 3, 2014
ATLANTA, Feb.3, 2014 /PRNewswire/ --Alimera Sciences, Inc. (NASDAQ: ALIM)
(Alimera), a biopharmaceutical company that specializes in the research,
development and commercialization of prescription ophthalmic pharmaceuticals,
today announced that it closed its previously announced private placement of
common stock on January 31, 2014. Gross proceeds from the offering were
approximately $37.5 million. Proceeds from the private placement are expected
to be used for general corporate and working capital purposes.
Alimera issued an aggregate of 6,250,000 newly-issued shares of common stock.
Cowen and Company, LLC served as sole placement agent for the transaction. In
connection with the private placement, Alimera has agreed, subject to certain
terms and conditions, to file a registration statement under the Securities
Act covering the resale of shares of common stock.
The securities offered have not been registered under the Securities Act and
may not be offered or sold in the United States without registration or an
applicable exemption from the registration requirements of the Securities Act.
This press release shall not constitute an offer to sell or the solicitation
of an offer to buy any securities of Alimera nor shall there be any sale of
securities in any state or jurisdiction in which such an offer, solicitation
or sale would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Alimera Sciences, Inc.
Alimera Sciences, Inc., headquartered in Alpharetta, Georgia, is a
biopharmaceutical company that specializes in the research, development and
commercialization of prescription ophthalmic pharmaceuticals.
Forward Looking Statements
This press release contains "forward-looking statements," within the meaning
of the Private Securities Litigation Reform Act of 1995, regarding, among
other things, the proposed use of proceeds from the private placement. Such
forward-looking statements are based on current expectations and involve
inherent risks and uncertainties, including factors that could delay, divert
or change any of them, and could cause actual results to differ materially
from those projected in its forward-looking statements. Meaningful factors
which could cause actual results to differ include risks related to Alimera's
need for additional capital in the future, as well as other factors discussed
in the "Risk Factors" and "Management's Discussion and Analysis of Financial
Condition and Results of Operations" sections of Alimera's Annual Report on
Form 10-K for the year ended December 31, 2012 and Quarterly Report on Form
10-Q for the quarter ended September 30, 2013, which are on file with the
Securities and Exchange Commission (SEC) and available on the SEC's website at
www.sec.gov. In addition to the risks described above and in Alimera's Annual
Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form
8-K and other filings with the SEC, other unknown or unpredictable factors
also could affect Alimera's results. There can be no assurance that the actual
results or developments anticipated by Alimera will be realized or, even if
substantially realized, that they will have the expected consequences to, or
effects on, Alimera. Therefore, no assurance can be given that the outcomes
stated in such forward-looking statements and estimates will be achieved.
All forward-looking statements contained in this press release are expressly
qualified by the cautionary statements contained or referred to herein.
Alimera cautions investors not to rely too heavily on the forward-looking
statements Alimera makes or that are made on its behalf. These forward-looking
statements speak only as of the date of this press release (unless another
date is indicated). Alimera undertakes no obligation, and specifically
declines any obligation, to publicly update or revise any such forward-looking
statements, whether as a result of new information, future events or
For press inquiries:
Katie Brazel, FleishmanHillard For investor inquiries:
John Mills, ICR
for Alimera Sciences for Alimera Sciences
SOURCE Alimera Sciences, Inc.
Press spacebar to pause and continue. Press esc to stop.